Hepatocellular carcinoma (HCC) is difficult to diagnose at an early stage, and its prognosis
is generally poor. Sorafenib is the primary treatment for unresectable advanced HCC and …

Purpose: To investigate the role of macrophages in tumor progression under sorafenib
treatment and to explore whether combination of drugs that deplete macrophages improved …

Background Post‐operative liver regeneration may contribute to tumor recurrence. There is
a theoretical need for an adjuvant therapy that can suppress tumor growth without adversely …

Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …

Background: Although sorafenib is adopted as the first-line treatment for unresectable liver
cancer, the antitumor efficacy is severely limited by the pro-invasive side effect. Methods: To …

Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest malignancy.
Sorafenib has demonstrated 44% survival advantage over placebo and has emerged as a …

Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …

Background Given the well-documented adverse side effects of sorafenib, many sorafenib-
treated patients may need the reduced initial dose of the compound, and an alternative …

HepG2 cells were treated with different concentrations of sorafenib or adriamycin alone or
their combination to investigate the inhibitory effect of sorafenib in combination with …

Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced
hepatocellular carcinoma (HCC). The present study was undertaken to determine whether …